Newron :: Reports, Presentations & Fact sheet

Discovering and developing innovative therapeutics for CNS disorders

Welcome to the Newron Pharmaceuticals website.
We are a clinical-stage biopharmaceutical company. Our shares are listed on the SIX Swiss Exchange (NWRN). Our mission is to discover, develop and commercialise novel drugs to treat diseases of the Central Nervous System (CNS) and pain.

Title:
Fact sheet 20/12/2007
Half-Year Report 2007 03/09/2007
Safinamide 18-Month Phase III results conference call MP 3 file 22/08/2007
Ralfinamide Positive Phase II results - Press confererence MP3 file 02/07/2007
Safinamide - Abstracts from Movement Disorder Society's 11th International Congress, Istanbul 07/06/2007
Safinamide, a New Anti-Parkinson Agent, is Effective and well-tolerated in Early Parkinson’s Disease PD Patients on a Stable Dose of a Single DA-Agonist: Results of a Randomized, International, Placebo-controlled, Phase III Trial. 10/05/2007
Full-Year Results 2006 - Press Conference MP3 File 29/03/2007
Annual Report 2006 27/03/2007

Home
Glossary
Search

Discovering and developing innovative therapeutics for CNS disorders

Investors

Reports, Presentations & Fact sheet - 2007

Fact sheet

Half-Year Report 2007

Safinamide 18-Month Phase III results conference call MP 3 file

Ralfinamide Positive Phase II results - Press confererence MP3 file

Safinamide - Abstracts from Movement Disorder Society's 11th International Congress, Istanbul

Safinamide, a New Anti-Parkinson Agent, is Effective and well-tolerated in Early Parkinson’s Disease PD Patients on a Stable Dose of a Single DA-Agonist: Results of a Randomized, International, Placebo-controlled, Phase III Trial.

Full-Year Results 2006 - Press Conference MP3 File

Annual Report 2006